Vectibix panitumumab: Phase II data

In the open-label, U.S. Phase II PRECEPT trial in 109 evaluable patients, 6 mg/kg Vectibix plus FOLFIRI (5-fluorouracil (5-FU), folinic acid and irinotecan) produced a 23% response rate in patients wi...